𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of mammalian target of rapamycin: The janus face of immunosuppression?

✍ Scribed by Christopher Soll; Pierre-Alain Clavien


Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
106 KB
Volume
51
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Mammalian target of rapamycin inhibition
✍ Corey Cutler; Joseph H. Antin πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 32 KB

P anwalkar and colleagues present a very complete overview on the evolving role of mammalian target of rapamycin (mTOR) inhibitors in the treatment of both hematologic and nonhematologic malignancies. We wish to clarify selected statements made by the authors. We would like to point out that all mT

Mammalian target of rapamycin inhibition
✍ Amit Panwalkar; Srdan Verstovsek; Francis J. Giles πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 588 KB

## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3‐kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal‐transduction pathways, is involved in the coupling of g

Curcumin inhibits the mammalian target o
✍ Christopher S. Beevers; Fengjun Li; Lei Liu; Shile Huang πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 546 KB

## Abstract Curcumin (diferuloylmethane), a polyphenol natural product of the plant __Curcuma longa__, is undergoing early clinical trials as a novel anticancer agent. However, the anticancer mechanism of curcumin remains to be elucidated. Here we show that curcumin inhibited growth of rhabdomyosar